Wilhelmina Children's Hospital/University Medical Center, Utrecht, the Netherlands.
Emerg Infect Dis. 2010 May;16(5):816-23. doi: 10.3201/eid1605.091223.
In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.
在荷兰，7 价肺炎球菌结合疫苗（PCV-7）于 2006 年 4 月 1 日后出生的婴儿的国家免疫计划中按照 3+1 剂次的方案实施。为了评估疫苗的效果，我们比较了疫苗实施前后（分别为 2004 年 6 月至 2006 年 6 月和 2006 年 6 月至 2008 年 6 月）的疾病发病率。我们对来自荷兰各地的 2552 株侵袭性肺炎球菌分离株进行了血清型分型，涵盖了该国 25%的人口。临床特征从医院记录中提取。2006 年 6 月后，适龄儿童的 PCV-7 疫苗血清型侵袭性肺炎球菌病（IPD）下降了 90%（95%置信区间为 68%-97%）；与此同时，非疫苗血清型 IPD 增加了 71%（无统计学意义），导致总 IPD 减少了 44%（95%置信区间为 7%-66%）。其他年龄组的 IPD 发生率没有变化。在荷兰，PCV-7 为接种疫苗的儿童提供了针对疫苗血清型 IPD 的高度保护，但非疫苗血清型 IPD 的增加降低了疫苗的净效益。
